Evidence map›Paper›PMID 41030347›Full record

ArticleFrontiers in psychology2025

Preliminary validation and refinement of the psychedelic aesthetic experience questionnaire.

Jake F Hooper, Jarrod M Ellingson, Kent E Hutchison

Abstract read
In one paragraph

Article in Frontiers in psychology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jake F HooperDepartment of Psychiatry, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Jarrod M EllingsonDepartment of Psychiatry, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Kent E HutchisonDepartment of Psychiatry, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Aesthetic experiences under psychedelics are often described as vivid, emotionally powerful, and meaningful, yet they remain under-measured in psychometric research. This study aimed to refine and validate the Psychedelic Aesthetic Experience Questionnaire (PAEQ), a novel instrument designed to assess the aesthetic dimensions of acute psychedelic experiences. Methods: A total of 365 past-year psilocybin users completed an anonymous online survey assessing their most typical psychedelic experience. Exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) were conducted on split samples to examine the latent structure of the PAEQ. Reliability, convergent validity, and regression models predicting self-reported psychological outcomes were evaluated. Results: EFA and CFA supported a four-factor structure reflecting sensory, affective, semantic, and flow dimensions. Internal consistency was high for the total scale (α = 0.90) and acceptable across subscales. Convergent validity was supported by strong correlations with MEQ ( Discussion: Despite some weaknesses, the PAEQ provides a psychometrically sound measure of aesthetic engagement during psychedelic experiences, a domain not fully captured by existing instruments. Its multidimensional structure grounded in the aesthetic triad and flow theory offers new avenues for assessing altered states of consciousness and their therapeutic relevance. Conclusion: The refined PAEQ is a valid tool for quantifying aesthetic aspects of psychedelic experiences and contributes to advancing empirical approaches for characterizing altered states of consciousness.

Indexed as

aestheticaffectflowPAEQperceptionpsychedelicpsychometrics

Identifiers

PMID41030347
PMCPMC12477130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.